
Genomix Thera, established in 2016 by Dr. Maximilian Fischer, is at the forefront of precision oncology, integrating CRISPR-Cas9 gene editing with quantum-guided nanoparticle delivery systems. The company focuses on personalized cancer therapies that target genomic alterations and modulate epigenetic factors, enhancing immune responses and addressing the tumor microenvironment. With successful Phase I trials for CRISPR-Nanobot therapy and an international patent for their AI-driven immunotherapy optimization algorithm, Genomix Thera is expanding its research facilities in Europe, positioning itself as a leader in the evolving landscape of cancer treatment.

Genomix Thera, established in 2016 by Dr. Maximilian Fischer, is at the forefront of precision oncology, integrating CRISPR-Cas9 gene editing with quantum-guided nanoparticle delivery systems. The company focuses on personalized cancer therapies that target genomic alterations and modulate epigenetic factors, enhancing immune responses and addressing the tumor microenvironment. With successful Phase I trials for CRISPR-Nanobot therapy and an international patent for their AI-driven immunotherapy optimization algorithm, Genomix Thera is expanding its research facilities in Europe, positioning itself as a leader in the evolving landscape of cancer treatment.
Founded: 2016
Headquarters: Berlin, Germany
Sector: Biotechnology — personalized cancer treatments
Tech focus: CRISPR-Cas9 gene editing and nanoparticle delivery
Recent funding activity: Seed round announced Jan 19, 2024
Personalized cancer treatment, tumor microenvironment modulation, immunotherapy optimization.
2016
Biotechnology
Seed round announced Jan 19, 2024